التداخل بين أوميبرازول وبيكربونات الصوديوم وفوريكونازول

Omeprazole (CYP2C19/3A4 Inhibition) Significantly Increased When initiating therapy with voriconazole in patients already receiving omeprazole doses of 40 mg or greater, reduce the omeprazole dose by one-half.

The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of other proton pump inhibitors.

Intervention: Voriconazole : Dosage adjustment of KONVOMEP is not usually required.

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] .

See full prescribing information for voriconazole.